Vamorolone

Vamorolone
Clinical data
Trade namesAgamree
Other namesVBP; VBP-15; 17α,21-Dihydroxy-16α-methylpregna-1,4,9(11)-triene-3,20-dione
AHFS/Drugs.comMonograph
MedlinePlusa624005
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
  • (8S,10S,13S,14S,16R,17R)-17-Hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-7,8,12,14,15,16-hexahydro-6H-cyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.032.874 Edit this at Wikidata
Chemical and physical data
FormulaC22H28O4
Molar mass356.462 g·mol−1
3D model (JSmol)
  • C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@]1(C(=O)CO)O)C)C
  • InChI=1S/C22H28O4/c1-13-10-18-16-5-4-14-11-15(24)6-8-20(14,2)17(16)7-9-21(18,3)22(13,26)19(25)12-23/h6-8,11,13,16,18,23,26H,4-5,9-10,12H2,1-3H3/t13-,16-,18+,20+,21+,22+/m1/s1
  • Key:ZYTXTXAMMDTYDQ-DGEXFFLYSA-N

Vamorolone, sold under the brand name Agamree, is a synthetic corticosteroid, which is used for the treatment of Duchenne muscular dystrophy.[4][5][6][7][8] It is taken by mouth.[1] It is a dual atypical glucocorticoid and antimineralocorticoid.[9]

The most common adverse reactions include cushingoid features, psychiatric disorders, vomiting, increased weight, and vitamin D deficiency.[10]

Vamorolone was approved for medical use in the United States in October 2023,[11][10] and in the European Union in December 2023.[2][3]

Medical uses

Vamorolone is indicated for the treatment of Duchenne muscular dystrophy.[1][10]

Available forms

Vamorolone is provided in the form of an oral suspension at a concentration of 40 mg/mL.[1]

Side effects

Side effects of vamorolone in clinical trials that occurred at a rate of 10% or greater included development of cushingoid features, psychiatric disorders, vomiting, weight gain, vitamin D deficiency, and cough.[1] The psychiatric disorders that occurred more frequently than with placebo included abnormal behavior, aggression, agitation, anxiety, irritability, altered mood, sleep disorder, and stereotypy.[1] In addition to the preceding side effects, vamorolone shows dose-dependent suppression of the hypothalamic–pituitary–adrenal axis (HPA axis) and hence has potential risks of adrenal suppression and adrenal insufficiency with discontinuation.[1] Vamorolone also shows immunosuppression and is expected to increase the risk of infection, among various other potential adverse effects.[1]

Adverse events observed more frequently in the treated cohort in clinical studies included adrenal suppression, cushingoid features, psychiatric disorders, vomiting, weight gain, and vitamin D deficiency, among others.[1]

Pharmacology

Pharmacodynamics

Vamorolone is a partial agonist of the glucocorticoid receptor with relative loss of transactivation activities, but retention of transrepression activities, compared to other glucocorticoids. As a result, it is described as possessing "dissociative" glucocorticoid properties.[9] In contrast to other corticosteroids, vamorolone is a potent antagonist of the mineralocorticoid receptor and hence has antimineralocorticoid activity.[9]

Vamorolone has anti-inflammatory and immunosuppressive effects as well as other glucocorticoid effects but is thought to lack certain other effects typical of glucocorticoids.[9][1]

Chemistry

Vamorolone is a synthetic corticosteroid and is also known by the chemical name 17α,21-dihydroxy-16α-methylpregna-1,4,9(11)-triene-3,20-dione or as 16α-methyl-9,11-dehydroprednisolone. It is a derivative of cortisol (hydrocortisone) and prednisolone (1,2-dehydrocortisol).

Anti-inflammatory drugs of the corticosteroid class show a carbonyl (=O) or hydroxyl (-OH) group on the C11 carbon of the steroid backbone. In contrast, vamorolone contains a Δ9,11 double bond between the C9 and C11 carbons. This change in structure has been shown to remove a molecular contact site with the glucocorticoid receptor, and leads to dissociative properties.[12]

History

In phase I clinical trials of adult volunteers, vamorolone was shown to be safe and well tolerated, with blood biomarker data suggesting possible loss of safety concerns of the corticosteroid class.[13]

In phase IIa dose-ranging clinical trial of 48 children with Duchenne muscular dystrophy (2 weeks on drug, 2 weeks off drug), vamorolone was shown to be safe and well tolerated, and showed blood biomarker data consistent with a myofiber membrane stabilization and anti-inflammatory effects, and possible loss of safety concerns.[14] These children continued on to a 24-week open-label extension study at the same doses, and this showed dose-dependent improvement of motor outcomes, with 2.0 and 6.0 mg/kg/day suggesting benefit.[15] These same children continued on a long-term extension study with dose escalations, and this suggested continued clinical improvement through 18-months treatment.[16]

Population pharmacokinetics (PK) of vamorolone was shown to fit to a 1-compartment model with zero-order absorption, with both adult men and young boys showing dose-linearity of PK parameters for the doses examined, and no accumulation of the drug during daily dosing. Apparent clearance averaged 2.0 L/h/kg in men and 1.7 L/h/kg in boys. Overall, vamorolone exhibited well-behaved linear PK, with similar profiles in healthy men and boys with DMD, moderate variability in PK parameters, and absorption and disposition profiles similar to those of classical glucocorticoids.[17] Exposure/response analyses have suggested that the motor outcome of time to stand from supine velocity showed the highest sensitivity to vamorolone, with the lowest AUC value providing 50% of maximum effect (E50 = 186 ng·h/mL), followed by time to climb 4 stairs (E50 = 478 ng·h/mL), time to run/walk 10 m (E50 = 1220 ng·h/mL), and 6-minute walk test (E50 = 1770 ng·h/mL). Week 2 changes of proinflammatory PD biomarkers showed exposure-dependent decreases. The E50 was 260 ng·h/mL for insulin-like growth factor-binding protein 2, 1200 ng·h/mL for matrix metalloproteinase 12, 1260 ng·h/mL for lymphotoxin α1/β2, 1340 ng·h/mL for CD23, 1420 ng·h/mL for interleukin-22-binding protein, and 1600 ng·h/mL for macrophage-derived chemokine/C-C motif chemokine 22.[18]

The US Food and Drug Administration (FDA) approved vamorolone based on evidence from a single clinical trial of 121 boys with DMD who were 4 to <7 years of age. The trial (Study 1) was conducted at 33 sites in 11 countries in Australia, Belgium, Canada, the Czech Republic, Spain, the United Kingdom, Greece, Israel, Netherlands, Sweden, and the United States.[10] In addition to Study 1, safety was also evaluated in a separate, open-label study of children with DMD aged 2 to <4 years (N=16) and children with DMD aged 7 to <18 years (N=16).[10]

Society and culture

In October 2023, the FDA approved vamorolone (Agamree; Santhera Pharmaceuticals) for the treatment of Duchenne muscular dystrophy.[11][19][20]

In October 2023, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Agamree, intended for the treatment of Duchenne muscular dystrophy.[2] The applicant for this medicinal product is Santhera Pharmaceuticals (Deutschland) GmbH.[2] Vamorolone was approved for medical use in the European Union in December 2023.[2][3]

Brand names

Vamorolone is the international nonproprietary name.[21]

Vamorolone is sold under the brand name Agamree.[1][2][3]

References

  1. ^ a b c d e f g h i j k "Agamree- vamorolone kit". DailyMed. 26 October 2023. Retrieved 20 November 2023.
  2. ^ a b c d e f "Agamree EPAR". European Medicines Agency. 12 October 2023. Retrieved 27 December 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  3. ^ a b c d "Agamree Product information". Union Register of medicinal products. 15 December 2023. Retrieved 26 December 2023.
  4. ^ "Vamorolone - ReveraGen Biopharma". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 7 October 2017. Retrieved 2 July 2017.
  5. ^ Reeves EK, Hoffman EP, Nagaraju K, Damsker JM, McCall JM (April 2013). "VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid". Bioorganic & Medicinal Chemistry. 21 (8): 2241–2249. doi:10.1016/j.bmc.2013.02.009. PMC 4088988. PMID 23498916.
  6. ^ Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, et al. (October 2013). "VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects". EMBO Molecular Medicine. 5 (10): 1569–1585. doi:10.1002/emmm.201302621. PMC 3799580. PMID 24014378.
  7. ^ Dadgar S, Wang Z, Johnston H, Kesari A, Nagaraju K, Chen YW, et al. (October 2014). "Asynchronous remodeling is a driver of failed regeneration in Duchenne muscular dystrophy". The Journal of Cell Biology. 207 (1): 139–158. doi:10.1083/jcb.201402079. PMC 4195829. PMID 25313409.
  8. ^ Damsker JM, Conklin LS, Sadri S, Dillingham BC, Panchapakesan K, Heier CR, et al. (September 2016). "VBP15, a novel dissociative steroid compound, reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis". Inflammation Research. 65 (9): 737–743. doi:10.1007/s00011-016-0956-8. PMID 27261270. S2CID 18698831.
  9. ^ a b c d Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, et al. (February 2019). "Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy". Life Sci Alliance. 2 (1): e201800186. doi:10.26508/lsa.201800186. PMC 6371196. PMID 30745312.
  10. ^ a b c d e "Drug Trials Snapshots: Agamree". U.S. Food and Drug Administration (FDA). 16 February 2024. Retrieved 14 March 2024. Public Domain This article incorporates text from this source, which is in the public domain.
  11. ^ a b "Drug Approval Package: Agamree". U.S. Food and Drug Administration (FDA). 7 November 2023. Archived from the original on 13 November 2023. Retrieved 13 November 2023.
  12. ^ Liu X, Wang Y, Gutierrez JS, Damsker JM, Nagaraju K, Hoffman EP, et al. (September 2020). "Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment". Proceedings of the National Academy of Sciences of the United States of America. 117 (39): 24285–24293. Bibcode:2020PNAS..11724285L. doi:10.1073/pnas.2006890117. PMC 7533876. PMID 32917814.
  13. ^ Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, et al. (June 2018). "Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes". Steroids. 134: 43–52. doi:10.1016/j.steroids.2018.02.010. PMC 6136660. PMID 29524454.
  14. ^ Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, et al. (October 2018). "Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug". Pharmacological Research. 136: 140–150. doi:10.1016/j.phrs.2018.09.007. PMC 6218284. PMID 30219580.
  15. ^ Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, et al. (September 2019). "Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function". Neurology. 93 (13): e1312 – e1323. doi:10.1212/WNL.0000000000008168. PMC 7011869. PMID 31451516.
  16. ^ Smith EC, Conklin LS, Hoffman EP, Clemens PR, Mah JK, Finkel RS, et al. (September 2020). "Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study". PLOS Medicine. 17 (9): e1003222. doi:10.1371/journal.pmed.1003222. PMC 7505441. PMID 32956407.
  17. ^ Mavroudis PD, van den Anker J, Conklin LS, Damsker JM, Hoffman EP, Nagaraju K, et al. (July 2019). "Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy". Journal of Clinical Pharmacology. 59 (7): 979–988. doi:10.1002/jcph.1388. PMC 6548694. PMID 30742306.
  18. ^ Li X, Conklin LS, van den Anker J, Hoffman EP, Clemens PR, Jusko WJ (October 2020). "Exposure-Response Analysis of Vamorolone (VBP15) in Boys With Duchenne Muscular Dystrophy". Journal of Clinical Pharmacology. 60 (10): 1385–1396. doi:10.1002/jcph.1632. PMC 7494537. PMID 32434278.
  19. ^ "FDA Approves Vamorolone for Treatment of Duchenne Muscular Dystrophy in Patients Aged 2 Years and Older". Pharmacy Times. 26 October 2023. Archived from the original on 27 October 2023. Retrieved 27 October 2023.
  20. ^ "Santhera Receives U.S. FDA Approval of Agamree (vamorolone) for the Treatment of Duchenne Muscular Dystrophy" (Press release). Santhera Pharmaceuticals Holding AG. 27 October 2023. Archived from the original on 31 October 2023. Retrieved 13 November 2023 – via GlobeNewswire.
  21. ^ World Health Organization (2017). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77". WHO Drug Information. 31 (1). hdl:10665/330984.
  • Clinical trial number NCT03439670 for "A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)" at ClinicalTrials.gov

Read other articles:

Serie B 2012-2013

Disambiguazione – Se stai cercando altri significati, vedi Serie B 2012-2013 (disambigua). Serie B 2012-2013Serie bwin 2012-2013 Competizione Serie B Sport Calcio Edizione 81ª Organizzatore Lega Serie B Date dal 24 agosto 2012al 2 giugno 2013 Luogo  Italia Partecipanti 22 Formula girone unico e play-off Sito web seriebwin.it/campionato Risultati Vincitore Sassuolo(1º titolo) Altre promozioni VeronaLivorno Retrocessioni VicenzaAscoliPro VercelliGrosseto Statistiche Miglior...

 

 

Bridgestone

Bridgestone CorporationKantor pusat Bridgestone di Tokyo Square Garden, TokyoNama asli株式会社ブリヂストンNama latinKabushiki gaisha BurijisutonJenisPublik KKKode emitenTYO: 5108Komponen TOPIX Large70IndustriSuku cadang mobil dan trukDidirikan1 Maret 1931; 93 tahun lalu (1931-03-01)Kurume, Fukuoka, JepangPendiriShojiro IshibashiKantorpusatKyobashi, Tokyo, JepangWilayah operasiSeluruh duniaTokohkunciMasaaki Tsuya(Chairman dan CEO)ProdukBan kendaraan bermotorPendapatan ¥3,337...

 

 

Alex McCarthy

Alex McCarthy Informasi pribadiNama lengkap Alex Simon McCarthy[1]Tanggal lahir 3 Desember 1989 (umur 34)Tempat lahir Guildford, InggrisTinggi 6 ft 4 in (1,93 m)Posisi bermain Penjaga gawangInformasi klubKlub saat ini SouthamptonNomor 13Karier junior?–2007 ReadingKarier senior*Tahun Tim Tampil (Gol)2007–2014 Reading 70 (0)2007 → Woking (pinjaman) 1 (0)2008 → Cambridge United (pinjaman) 1 (0)2008 → Team Bath (pinjaman) ? (?)2009 → Aldershot Town (pinjam...

Sultan Bachtiar Najamudin

Artikel ini membutuhkan rujukan tambahan agar kualitasnya dapat dipastikan. Mohon bantu kami mengembangkan artikel ini dengan cara menambahkan rujukan ke sumber tepercaya. Pernyataan tak bersumber bisa saja dipertentangkan dan dihapus.Cari sumber: Sultan Bachtiar Najamudin – berita · surat kabar · buku · cendekiawan · JSTOR (November 2022) Sultan Baktiar NajamudinPotret sebagai Anggota Dewan Perwakilan Daerah periode 2019-2024 Wakil Ketua Dewan Perwaki...

 

 

برنارد تابي

برنارد تابي (بالفرنسية: Bernard Tapie)‏  مناصب رئيس   في المنصبأبريل 1986  – ديسمبر 1994  في أولمبيك مارسيليا  جان كاريو  [لغات أخرى]‏  بيير كانجيوني  [لغات أخرى]‏  عضو الجمعية الوطنية الفرنسية   عضو خلال الفترة29 يونيو 1989  – 2 أبريل 1992  الدائرة ا�...

 

 

Eparki Thamarassery

Eparki ThamarasseryLokasiNegaraIndiaMetropolitEparki Agung TellicherryStatistikLuas5.893 km2 (2.275 sq mi)Populasi- Total- Katolik(per 2004)5.749.275124,664 (2.2%)InformasiRitusSiro-MalabarKepemimpinan kiniPausFransiskusUskupRemigius Inchananiyil Eparki Katolik Siro-Malabar Thamarassery adalah sebuah eparki Katolik Timur di India, di bawah Gereja Katolik Siro-Malabar. Eparki tersebut dibentuk pada 28 April 1986. Pranala luar Syro-Malabar Catholic Diocese of ...

Indie occidentali

Disambiguazione – Se stai cercando lo stato esistito dal 1958 al 1962, vedi Federazione delle Indie Occidentali. Questa voce o sezione sull'argomento America non cita le fonti necessarie o quelle presenti sono insufficienti. Puoi migliorare questa voce aggiungendo citazioni da fonti attendibili secondo le linee guida sull'uso delle fonti. Segui i suggerimenti del progetto di riferimento. Indie occidentaliStati Giamaica Cuba Haiti Rep. Dominicana Antigua e Barb...

 

 

The Circus: Inside the Greatest Political Show on Earth

American television documentary series The Circus (TV series) redirects here. For the Indian drama series, see Circus (Indian TV series). The Circus: Inside the Greatest Political Show on EarthAlso known asThe CircusGenreDocumentaryPresented by Mark Halperin(seasons 1–2) John Heilemann(seasons 1–8) Mark McKinnon(seasons 1–8) Alex Wagner(seasons 3–7) Jennifer Palmieri(seasons 6–8) Country of originUnited StatesOriginal languageEnglishNo. of seasons8No. of episodes130ProductionRunning...

 

 

Robert M. La Follette School of Public Affairs

Public policy school of the University of Wisconsin–Madison La Follette School redirects here. Not to be confused with La Follette High School. Robert M. La Follette School of Public AffairsTypePublicEstablished1967 (1999)DirectorSusan Webb YackeeAcademic staff22Students110LocationMadison, Wisconsin, United StatesCampusUniversity of Wisconsin–MadisonWebsitewww.lafollette.wisc.edu The Robert M. La Follette School of Public Affairs, commonly known as the La Follette School, is a public grad...

VCR

Video Cassette Recording Une cassette pour VCR, VCR-LP et Super Video. Type de média Cassette vidéo Codage PAL Norme 625 lignes Développé par Philips modifier  Magnétoscope Philips N1500 Le VCR (ou Video Cassette Recording) est un standard pour l'enregistrement de vidéo analogique sur bande magnétique de 1/2 pouce qui a été mis au point par Philips en 1972. Il est commercialisé sur le marché français en 1975. Une version VCR LP (VCR-Long Play) est lancée en 1976. Précurseu...

 

 

FM transmitter (personal device)

Belkin TuneCast transmitter, for use with any device which has a 3.5mm headphone jack. Frequency range is 88.1 - 88.3 - 88.5 - 88.7 MHz Belkin TuneCastII FM Transmitter with a modified antenna connected to an iPod music player. A personal FM transmitter is a low-power FM radio transmitter that broadcasts a signal from a portable audio device (such as an MP3 player) to a standard FM radio. Most of these transmitters plug into the device's headphone jack and then broadcast the signal over an FM...

 

 

Politique étrangère des États-Unis

Carte des postes diplomatiques américains à l'étranger, en 2003. La politique étrangère des États-Unis (en anglais : foreign policy of the United States ou United States foreign policy) est la politique étrangère menée par les États-Unis vis-à-vis des États tiers et du système multilatéral mondial. Elle constitue le résultat d'un processus d'élaboration complexe, fait de débats contradictoires tranchés par des arbitrages. D'autre part, le système constitutionnel améri...

Lady Gaga

Untuk serangga dengan nama yang sama, lihat Aleiodes gaga. Lady GagaGaga pada tahun 2021Informasi latar belakangNama lahirStefani Joanne Angelina GermanottaLahir28 Maret 1986 (umur 38)Kota New York,  Amerika SerikatAsalManhattan,  New YorkGenrePop, dance, elektronikPekerjaan Penyanyi Pencipta lagu Aktris Produser Instrumen Vokal Piano Gitar Tahun aktif2001–sekarangLabelUniversal Music GroupSitus webwww.ladygaga.com Stefani Joanne Angelina Germanotta[a] (lahir 28 Maret...

 

 

أحمد مدغري

أحمد مدغري أول وزير للداخلية الجزائرية في المنصب20 يونيو 1965 – 10 ديسمبر 1974(9 سنواتٍ و5 أشهرٍ و20 يومًا) الرئيس أحمد بن بلةهواري بومدين الحكومة حكومة بن بلة الأولىحكومة بن بلة الثانيةحكومة بومدين الأولىحكومة بومدين الثانيةحكومة بومدين الثالثة أحمد بن بلة محمد بن أحمد عبد الغن...

 

 

Favorite Story

American old-time radio dramatic anthology Radio show Favorite StoryRonald Colman, host of Favorite StoryGenreDramatic anthologyRunning time30 minutesCountry of originUnited StatesLanguage(s)EnglishHome stationKFISyndicatesZiv CompanyHosted byRonald ColmanAnnouncerGeorge BarclayTrue BoardmanWritten byJerome LawrenceRobert E. LeeWilliam FrougE. Jack NeumanDirected byJerome LawrenceRobert E. LeeProduced byJerome LawrenceRobert E. LeeOriginal release1946 –1949No. of episodes118 Favorite S...

2024 European Wrestling Championships – Women's freestyle 68 kg

Wrestling competition 2024 EuropeanWrestling ChampionshipsFreestyleGreco-RomanWomen57 kg55 kg50 kg61 kg60 kg53 kg65 kg63 kg55 kg70 kg67 kg57 kg74 kg72 kg59 kg79 kg77 kg62 kg86 kg82 kg65 kg92 kg87 kg68 kg97 kg97 kg72 kg125 kg130 kg76 kgvte Main article: 2024 European Wrestling Championships The women's freestyle 68 kg is a competition featured at the 2024 European Wrestling Championships, and held in Bucharest, Romania on February 14 and 15.[1] Medalists Gold  Buse Tosun Çav...

 

 

International rankings of Israel

Overview of international rankings of Israel The following are international rankings of  Israel: This list is incomplete; you can help by adding missing items. (December 2013) Agriculture The Economist: Global Food Security Index, ranked 19th out of 113 in 2017[1] Economy Aerial view of Tel Aviv Main article: Economy of Israel International Monetary Fund: GDP (nominal) 2022, ranked 28th out of 216 countries[2] International Monetary Fund: GDP (nominal) per capita 2022, r...

 

 

Kanonik (imam)

Kanonik Petrus-Ludovicus Stillemans (1821-1902), seorang kanonik Seminari, Sint Niklaas, Flanders. Kanonik (dari bahasa Latin canonicus, yang berasal dari bahasa Yunani κανονικός, kanonikós, berkaitan dengan suatu peraturan, secara rutin) adalah seorang imam Gereja Katolik atau Komuni Anglikan yang merupakan anggota dari suatu ordo yang diatur oleh seperangkat peraturan gerejawi (hukum kanonik). Pranala luar Canons Regular of the Immaculate Conception Canons Regular of Premontre, Or...

Kellian van der Kaap

Dutch footballer In this Dutch name, the surname is van der Kaap, not Kaap. Kellian van der Kaap van der Kaap warming up for Levski in 2022Personal informationDate of birth (1998-11-08) 8 November 1998 (age 25)[1]Place of birth Groningen, NetherlandsHeight 1.90 m (6 ft 3 in)[2]Position(s) Centre-backTeam informationCurrent team Levski SofiaNumber 5Youth career0000–2009 SV Marum[3]2009–2010 Cambuur[3]2010–2011 Groningen[3]2011�...

 

 

Jalan Jerangau Barat

Road in Malaysia Federal Route 1689Jalan Jerangau BaratMajor junctionsNortheast endKampung Bukit PayungMajor intersections FT 14 Jerangau HighwaySouthwest endFELDA Jerangau Barat LocationCountryMalaysia Highway system Highways in Malaysia Expressways Federal State Jalan Jerangau Barat, Federal Route 1689, is a federal road in Terengganu, Malaysia. At most sections, the Federal Route 1689 was built under the JKR R5 road standard, with a speed limit of up to 90 km/h. List of junc...